Rein Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
12407 N. MOPAC EXPY., AUSTIN, TX, 78758
Mailing Address
12407 N. MOPAC EXPY., AUSTIN, TX, 78758
Phone
7378021989
Fiscal Year End
1231
EIN
134196017
Financial Overview
FY2025
-$49.87M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | January 16, 2026 | View on SEC |
| 8-K Current report of material events | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | November 18, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 3, 2025 | View on SEC |
| 4 Insider stock transaction report | October 28, 2025 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Strategic pivot to LTI-03 peptide platform for pulmonary fibrosis
- Successful $15 million capital raise to extend operations into Q2 2026
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.